Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2017

View Archived Issues

Heat Biologics set to acquire Pelican Therapeutics

Diamyd Medical invests in NextCell Pharma

Eurostars grant awarded to international consortium developing antibody-drug conjugates

YY-1 protein as a potential prognostic marker in Wilms' tumor

ImmunoMet Therapeutics raises series B financing

Inhibikase receives research grant from The Michael J. Fox Foundation

IDO-1, a potential biomarker for cancer of the biliary tract

Pharnext and Galapagos collaborate to generate pipeline of synergistic drug combinations

First-in-human study of AAGP-treated islet cells for type 1 diabetes

Beijing Hanmi Pharmaceutical patents IRAK-4 inhibitors

Karyopharm Therapeutics presents serine/threonine-protein kinase modulators

FORUM Pharmaceuticals discovers oxadiazine compounds

PKU HealthCare Industry Group presents phosphatidylinositol 3-kinase alpha inhibitors

Janssen Pharmaceutica identifies protein arginine N-methyltransferase 5 inhibitors

Bavarian Nordic and Roche collaborate to study Tecentriq with CV-301 for bladder cancer

Synairgen reports new data from LOXL2 enzyme inhibitor program in IPF

Vasodilator-stimulated phosphoprotein as potential diagnostic marker for papillary thyroid carcinoma

CD163-positive M2-like macrophages correlate with patient survival in esophageal adenocarcinoma

FDA clears IND for UCART-19

Zinplava approved in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...